Today: 21 May 2026
Affirm (AFRM) crushes Q1 FY2026, extends Amazon deal to 2031 — shares whipsaw on Nov. 7, 2025
7 November 2025
2 mins read

Affirm (AFRM) crushes Q1 FY2026, extends Amazon deal to 2031 — shares whipsaw on Nov. 7, 2025

  • Beat: EPS $0.23 vs. $0.11 est.; revenue $933.3M (+34% YoY).
  • Growth: GMV +42% to $10.8B; Affirm Card users hit 2.8M with $1.4B Card GMV.
  • Guidance: Q2 FY26 revenue $1.03–$1.06B; FY26 GMV raised to > $47.5B; adj. op. margin outlook > 27.1%.
  • Partnerships: U.S. Amazon agreement extended five years (Feb. 2026–Jan. 2031); auto‑renews annually thereafter.
  • Today’s trading: After an early pop, AFRM reversed lower intraday (see live chart above for latest). As of early afternoon, Reuters showed ~–7.8% on the day.

What happened today

Affirm Holdings (NASDAQ: AFRM) dominated headlines after reporting a blowout Q1 FY2026 (quarter ended Sept. 30, 2025). The company topped Wall Street on both the top and bottom lines and lifted its full‑year outlook, citing momentum in its 0% APR offers, the Affirm Card, and large‑platform partnerships.

Adding to the news flow, Affirm disclosed that it restated and extended its U.S. partnership with Amazon. The new agreement takes effect Feb. 1, 2026, runs through Jan. 2031, and automatically renews in one‑year increments unless terminated—further cementing Affirm’s presence across Amazon’s checkout and Amazon Pay surfaces.

Markets initially cheered the beat—pre‑market gains topped 8%—but sentiment flipped as the session wore on, with shares sliding by mid‑day amid broader tech volatility and debate over the guidance pace (see live price widget above).


By the numbers: Q1 FY2026

  • Revenue:$933.3M (+34% YoY) vs. $883M consensus.
  • EPS:$0.23 vs. $0.11 expected; a sharp improvement from a ($0.31) loss a year ago.
  • GMV:$10.8B (+42% YoY).

Affirm Card & user metrics

  • Affirm Card GMV: $1.4B; active cardholders:2.8M.
  • Total active consumers:~24.1M (Affirm Card now accounts for ~11.6% of that base).

Merchant ecosystem

  • Active merchants:~419,000, up 30% YoY, helped by wallet integrations and new ISV partners.

Guidance & outlook

  • Q2 FY2026 (Dec. quarter): revenue $1.03–$1.06B (around in‑line at the midpoint).
  • FY2026: GMV outlook raised to > $47.5B (from > $46B); adjusted operating margin now seen > 27.1% (prior 26.1%).
  • Unit economics: Management continues to target a “revenue‑less‑transaction‑costs” (RLTC) upper bound of ~4%—a key guardrail for sustainable growth. Seeking Alpha+1

Why it matters: The improved FY26 targets and the Amazon extension through 2031 provide visibility for volume and engagement, while the Card’s rapid adoption diversifies Affirm’s revenue mix beyond classic BNPL at checkout.


Street reaction

  • Citi Research flagged strong profitability, 42% GMV growth, and traction in 0% APR and the debit card as notable positives.
  • Morgan Stanley kept Equal‑Weight but trimmed its price target to $83, reflecting valuation and execution balance after the run‑up into earnings.

What to watch next

  1. Consumer credit quality into the holiday quarter (delinquencies/charge‑offs are the swing factor for BNPL names).
  2. Card penetration: whether Affirm Card can keep growing above 100% YoY GMV and add materially to revenue.
  3. Partner funnel: Amazon’s extension is a long‑term anchor; watch for incremental wallet/checkout placements with top merchants to drive GMV density.
  4. Margin discipline: tracking progress against the >27% adjusted operating‑margin goal and ~4% RLTC ceiling through FY26.

Sources: Company press materials and filings; major financial outlets and data services covering today’s developments on Affirm.

Disclosure: This article is for information purposes only and is not investment advice.

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

Stock Market Today

  • SpaceX IPO Filing Reveals Financials, Musk Could Become First Trillionaire
    May 20, 2026, 7:08 PM EDT. SpaceX filed for an initial public offering (IPO), disclosing its finances and board members for the first time. The company reported $18.7 billion in revenue for 2025, up 33% year-on-year, but posted a net loss of $4.9 billion, reversing a $791 million profit in 2024. First-quarter 2026 losses reached $4.3 billion on $4.7 billion revenue. The IPO, trading as SPCX, may become the largest ever, potentially boosting Elon Musk's wealth to trillionaire status. SpaceX aims to fund its ambitious plans including Starlink satellite network expansion, AI infrastructure, and establishing extraterrestrial colonies.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Take‑Two Interactive (TTWO) Slides as ‘GTA VI’ Slips to Nov. 19, 2026—Despite Record Q2 Bookings and Full‑Year Guidance Raise (Nov. 7, 2025)
Previous Story

Take‑Two Interactive (TTWO) Slides as ‘GTA VI’ Slips to Nov. 19, 2026—Despite Record Q2 Bookings and Full‑Year Guidance Raise (Nov. 7, 2025)

NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook
Next Story

Nvidia (NVDA) Stock Today — November 7, 2025: Closes Near $188 As China Sales Face New Blocks, AI-Spending Jitters Weigh On Tech

Go toTop